Cronos Group Reports Q1 2026 Financial Results

TORONTO – Cronos Group Inc. posted record net revenue and gross profit for the first quarter of 2026, driven by higher sales volumes, a favorable product mix, and gains in key markets.

The Cannabis company disclosed a sharply positive earnings report, posting first-quarter 2026 net revenue of $45.2 million, a 40% increase year-over-year that beat analyst expectations of $42.29 million. Gross profit came in at $19.2 million and net income reached $15.7 million. Adjusted EBITDA rose to $5.1 million, up 122% compared to Q1 2025. On the balance sheet, the company ended the quarter with $821.9 million in cash and no reported debt, a position that sets Cronos apart from most of its publicly traded Cannabis peers.

The clearest growth engine this quarter was international. Cronos Israel delivered a record quarter, with the PEACE NATURALS® brand expanding its lead in the Israeli medical Cannabis market and generating net revenue growth of 53% year-over-year – the company’s 9th consecutive record quarter in the country. In international markets outside Israel, net revenue grew 97% year-over-year, reaching record levels.

On the domestic front, the Spinach® brand held 5.5% total national market share in Canada, maintaining its position as the country’s #2 Cannabis brand overall. Its most significant achievement in Q1 was reaching #1 in the vape category for the first time, capturing 9.8% total vape market share across all formats. Flower share also moved. Spinach® rose to #3 in the flower category with 5% market share, reflecting increased product availability following the Cronos GrowCo expansion. Premium brand Lord Jones® showed selective strength, holding a 9.1% share in chocolate Cannabis edibles in Canada and making its entry into the Israeli medical Cannabis market, where its five premium flower strains met strong patient demand.

The quarter’s unresolved storyline is the pending acquisition of CanAdelaar B.V., the largest Cannabis operator within the Netherlands’ adult-use pilot program. The deal, announced in December 2025, carries an upfront price of $67 million and would give Cronos the #1 market share position in the largest adult-use Cannabis market in Europe. Cronos extended the closing deadline from June 9 to September 9, 2026, to allow more time for regulatory clearances, license confirmations, and completion of the Dutch Bibob review – a background screening process required by Dutch authorities for participants in regulated industries. The delay is bureaucratic, not commercial, but it keeps a meaningful piece of the company’s European strategy in an unresolved state.

Management is directing some of its cash surplus back to shareholders. Cronos repurchased 6.4 million common shares for $16.7 million during the quarter, and the board authorized a new $50 million repurchase program set to commence May 14, 2026.

Overall, Cronos enters Q2 with a rare combination of profitability, an unencumbered balance sheet, and geographic diversification that is already generating returns. The CanAdelaar delay bears watching [Dutch regulatory timelines have a history of slipping] but the company’s core operations in Israel, Canada, and broader Europe are doing the heavy lifting in the meantime.